Early-Stage trial halted for advanced skin cancer treatment

NCT ID NCT04913220

Summary

This early-stage study tested a new two-drug combination (SAR444245 with cemiplimab) for people with advanced melanoma or squamous cell skin cancer that had spread and could not be removed by surgery. The main goal was to see if the combination could shrink tumors and determine a safe dose. The study was terminated early and enrolled 46 participants.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beverly Hills Cancer Center & Optima Diagnostic Imaging Site Number : 8400007

    Beverly Hills, California, 90211, United States

  • Investigational Site Number : 0360001

    Macquarie University, New South Wales, 2109, Australia

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, 8420383, Chile

  • Investigational Site Number : 1520002

    Santiago, Reg Metropolitana de Santiago, 7500921, Chile

  • Investigational Site Number : 1520003

    Temuco, 4800827, Chile

  • Investigational Site Number : 1520004

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520005

    Santaigo, Reg Metropolitana de Santiago, 8241470, Chile

  • Investigational Site Number : 1520006

    Antofagasta, 1420000, Chile

  • Investigational Site Number : 2500001

    Nantes, 44093, France

  • Investigational Site Number : 2500002

    Dijon, 21079, France

  • Investigational Site Number : 2500003

    Bobigny, 93009, France

  • Investigational Site Number : 2500005

    Lille, 59037, France

  • Investigational Site Number : 2500006

    Pierre-Bénite, 69495, France

  • Investigational Site Number : 2760001

    Hamburg, 20246, Germany

  • Investigational Site Number : 2760003

    Mannheim, 68167, Germany

  • Investigational Site Number : 2760004

    Berlin, 10117, Germany

  • Investigational Site Number : 2760005

    München, 80337, Germany

  • Investigational Site Number : 2760006

    Minden, 32429, Germany

  • Investigational Site Number : 3800001

    Naples, 80131, Italy

  • Investigational Site Number : 3800004

    Perugia, 06126, Italy

  • Investigational Site Number : 7240001

    Barcelona, Barcelona [Barcelona], 08035, Spain

  • Investigational Site Number : 7240002

    Santander, Cantabria, 39008, Spain

  • Investigational Site Number : 7240003

    L'Hospitalet de Llobregat, Barcelona [Barcelona], 08908, Spain

  • Investigational Site Number : 7240004

    Barcelona, Barcelona [Barcelona], 08036, Spain

Conditions

Explore the condition pages connected to this study.